Literature DB >> 24211834

BAP1 is phosphorylated at serine 592 in S-phase following DNA damage.

Ziad M Eletr1, Luming Yin, Keith D Wilkinson.   

Abstract

The human BAP1 deubiquitinating enzyme is a chromatin-bound transcriptional regulator and tumor suppressor. BAP1 functions in suppressing cell proliferation, yet its role in the DNA damage response pathway is less understood. In this study we characterized DNA damage-induced phosphorylation of BAP1 at serine 592 (pS592) and the cellular outcomes of this modification. In contrast to the majority of BAP1, pS592-BAP1 is predominantly dissociated from chromatin. Our findings support a model whereby stress induced phosphorylation functions to displace BAP1 from specific promoters. We hypothesize that this regulates the transcription of a subset of genes involved in the response to DNA damage.
© 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BAP1; DNA damage; Deubiquitinating enzyme; Phosphorylation; Ubiquitin

Mesh:

Substances:

Year:  2013        PMID: 24211834      PMCID: PMC3923164          DOI: 10.1016/j.febslet.2013.10.035

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  25 in total

1.  Profiling of UV-induced ATM/ATR signaling pathways.

Authors:  Matthew P Stokes; John Rush; Joan Macneill; Jian Min Ren; Kam Sprott; Julie Nardone; Vicky Yang; Sean A Beausoleil; Steven P Gygi; Mark Livingstone; Hui Zhang; Roberto D Polakiewicz; Michael J Comb
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

Review 2.  ATR: an essential regulator of genome integrity.

Authors:  Karlene A Cimprich; David Cortez
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07-02       Impact factor: 94.444

3.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.

Authors:  D E Jensen; M Proctor; S T Marquis; H P Gardner; S I Ha; L A Chodosh; A M Ishov; N Tommerup; H Vissing; Y Sekido; J Minna; A Borodovsky; D C Schultz; K D Wilkinson; G G Maul; N Barlev; S L Berger; G C Prendergast; F J Rauscher
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

4.  Valosin-containing protein phosphorylation at Ser784 in response to DNA damage.

Authors:  Mark Livingstone; Hong Ruan; Jessica Weiner; Karl R Clauser; Peter Strack; Shengfang Jin; Amy Williams; Heidi Greulich; James Gardner; Monica Venere; Tamara A Mochan; Richard A DiTullio; Katarina Moravcevic; Vassilis G Gorgoulis; Anne Burkhardt; Thanos D Halazonetis
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

5.  Substrate specificities and identification of putative substrates of ATM kinase family members.

Authors:  S T Kim; D S Lim; C E Canman; M B Kastan
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

6.  Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis.

Authors:  V Bianchi; E Pontis; P Reichard
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

7.  Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1.

Authors:  Shahram Misaghi; Søren Ottosen; Anita Izrael-Tomasevic; David Arnott; Mohamed Lamkanfi; James Lee; Jinfeng Liu; Karen O'Rourke; Vishva M Dixit; Angus C Wilson
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

8.  BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.

Authors:  Hiroyuki Nishikawa; Wenwen Wu; Ayaka Koike; Ryoko Kojima; Hiromichi Gomi; Mamoru Fukuda; Tomohiko Ohta
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

9.  ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.

Authors:  Shuhei Matsuoka; Bryan A Ballif; Agata Smogorzewska; E Robert McDonald; Kristen E Hurov; Ji Luo; Corey E Bakalarski; Zhenming Zhao; Nicole Solimini; Yaniv Lerenthal; Yosef Shiloh; Steven P Gygi; Stephen J Elledge
Journal:  Science       Date:  2007-05-25       Impact factor: 47.728

10.  BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.

Authors:  Karen H Ventii; Narra S Devi; Kenneth L Friedrich; Tatiana A Chernova; Mourad Tighiouart; Erwin G Van Meir; Keith D Wilkinson
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

View more
  18 in total

Review 1.  Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Authors:  Sebastian Walpole; Antonia L Pritchard; Colleen M Cebulla; Robert Pilarski; Meredith Stautberg; Frederick H Davidorf; Arnaud de la Fouchardière; Odile Cabaret; Lisa Golmard; Dominique Stoppa-Lyonnet; Erin Garfield; Ching-Ni Njauw; Mitchell Cheung; Joni A Turunen; Pauliina Repo; Reetta-Stiina Järvinen; Remco van Doorn; Martine J Jager; Gregorius P M Luyten; Marina Marinkovic; Cindy Chau; Miriam Potrony; Veronica Höiom; Hildur Helgadottir; Lorenza Pastorino; William Bruno; Virginia Andreotti; Bruna Dalmasso; Giulia Ciccarese; Paola Queirolo; Luca Mastracci; Karin Wadt; Jens Folke Kiilgaard; Michael R Speicher; Natasha van Poppelen; Emine Kilic; Rana'a T Al-Jamal; Irma Dianzani; Marta Betti; Carsten Bergmann; Sandro Santagata; Sonika Dahiya; Saleem Taibjee; Jo Burke; Nicola Poplawski; Sally J O'Shea; Julia Newton-Bishop; Julian Adlard; David J Adams; Anne-Marie Lane; Ivana Kim; Sonja Klebe; Hilary Racher; J William Harbour; Michael L Nickerson; Rajmohan Murali; Jane M Palmer; Madeleine Howlie; Judith Symmons; Hayley Hamilton; Sunil Warrier; William Glasson; Peter Johansson; Carla Daniela Robles-Espinoza; Raul Ossio; Annelies de Klein; Susana Puig; Paola Ghiorzo; Maartje Nielsen; Tero T Kivelä; Hensin Tsao; Joseph R Testa; Pedram Gerami; Marc-Henri Stern; Brigitte Bressac-de Paillerets; Mohamed H Abdel-Rahman; Nicholas K Hayward
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

2.  Dissenting degradation: Deubiquitinases in cell cycle and cancer.

Authors:  Thomas Bonacci; Michael J Emanuele
Journal:  Semin Cancer Biol       Date:  2020-03-20       Impact factor: 15.707

Review 3.  Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.

Authors:  K Rai; R Pilarski; C M Cebulla; M H Abdel-Rahman
Journal:  Clin Genet       Date:  2015-07-14       Impact factor: 4.438

Review 4.  Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.

Authors:  Alexandra M Haugh; Ching-Ni Njauw; Jeffrey A Bubley; Anna Elisa Verzì; Bin Zhang; Emily Kudalkar; Timothy VandenBoom; Kara Walton; Brian L Swick; Raj Kumar; Huma Q Rana; Sarah Cochrane; Shelley R McCormick; Christopher R Shea; Hensin Tsao; Pedram Gerami
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

5.  BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability.

Authors:  Shin-Ai Lee; Daye Lee; Minhwa Kang; Sora Kim; Su-Jung Kwon; Han-Sae Lee; Hye-Ran Seo; Prashant Kaushal; Nam Soo Lee; Hongtae Kim; Cheolju Lee; Jongbum Kwon
Journal:  Cell Death Differ       Date:  2022-05-30       Impact factor: 15.828

6.  BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma.

Authors:  Lauren E Langbein; Rayan El Hajjar; Shen He; Eleonora Sementino; Zhijiu Zhong; Wei Jiang; Benjamin E Leiby; Li Li; Robert G Uzzo; Joseph R Testa; Haifeng Yang
Journal:  Cancer Lett       Date:  2022-08-20       Impact factor: 9.756

7.  The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.

Authors:  Salima Daou; Ian Hammond-Martel; Nazar Mashtalir; Haithem Barbour; Jessica Gagnon; Nicholas V G Iannantuono; Nadine Sen Nkwe; Alena Motorina; Helen Pak; Helen Yu; Hugo Wurtele; Eric Milot; Frédérick A Mallette; Michele Carbone; El Bachir Affar
Journal:  J Biol Chem       Date:  2015-09-28       Impact factor: 5.157

8.  Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Authors:  A Gordon Robertson; Juliann Shih; Christina Yau; Ewan A Gibb; Junna Oba; Karen L Mungall; Julian M Hess; Vladislav Uzunangelov; Vonn Walter; Ludmila Danilova; Tara M Lichtenberg; Melanie Kucherlapati; Patrick K Kimes; Ming Tang; Alexander Penson; Ozgun Babur; Rehan Akbani; Christopher A Bristow; Katherine A Hoadley; Lisa Iype; Matthew T Chang; Andrew D Cherniack; Christopher Benz; Gordon B Mills; Roel G W Verhaak; Klaus G Griewank; Ina Felau; Jean C Zenklusen; Jeffrey E Gershenwald; Lynn Schoenfield; Alexander J Lazar; Mohamed H Abdel-Rahman; Sergio Roman-Roman; Marc-Henri Stern; Colleen M Cebulla; Michelle D Williams; Martine J Jager; Sarah E Coupland; Bita Esmaeli; Cyriac Kandoth; Scott E Woodman
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

Review 9.  Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?

Authors:  Chen-Xi Zhao; Chen-Ming Zeng; Ke Wang; Qiao-Jun He; Bo Yang; Fan-Fan Zhou; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-06-29       Impact factor: 6.150

Review 10.  Fine-tuning the ubiquitin code at DNA double-strand breaks: deubiquitinating enzymes at work.

Authors:  Elisabetta Citterio
Journal:  Front Genet       Date:  2015-09-08       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.